

# Amubarvimab/romlusevimab for COVID-19: real-time meta-analysis of 4 studies

@CovidAnalysis, June 2026, Version 4, c19early.org/ammeta.html

## Abstract

Significantly lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit.

Meta-analysis using the most serious outcome reported shows 25% [-70-66%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials and higher quality studies. Early treatment shows efficacy while late treatment does not, consistent with expectations for an antiviral treatment.


Currently there is limited data, with only 31 control events for the most serious outcome in trials to date.

**Efficacy is variant dependent.** mAb use may create new variants that spread globally<sup>1-3</sup>, and may be associated with increased risk of autoimmune disease<sup>4</sup>, prolonged viral loads, clinical deterioration, and immune escape<sup>2,5-9</sup>.


No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

## Evolution of COVID-19 clinical evidence

Meta-analysis results over time



## Serious Outcome Risk



## AMUBARVIMAB/ROMLUSEVIMAB FOR COVID-19 — HIGHLIGHTS

Amubarvimab/romlusevimab reduced risk with low confidence for viral clearance.


**Efficacy is variant dependent.** Amubarvimab/romlusevimab may have reduced or no activity for recent variants.

Real-time updates and corrections with a consistent protocol for 223 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

## Introduction

### Immediate treatment recommended

SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological injury<sup>11-27</sup> and cognitive deficits<sup>14,19</sup>, cardiovascular complications<sup>28-34</sup>, DNA damage<sup>35-38</sup>, organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits<sup>39</sup>—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Minimizing replication as early as possible is recommended.



**Fig. 1.** SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from<sup>10</sup>.

### Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 500+ host and viral proteins and other factors<sup>A,40-47</sup>, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 11,000 compounds may reduce COVID-19 risk<sup>48</sup>, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

### Monoclonal antibodies

Amubarvimab/romlusevimab is a combination of two monoclonal antibodies (mAbs). mAbs are laboratory-engineered proteins designed to mimic the immune system's ability to fight pathogens. In the context of COVID-19, mAbs typically target specific regions of the SARS-CoV-2 spike protein, inhibiting

	Bamlanivimab/ etesevimab	Casirivimab/ imdevimab	Sotrovimab	Bebtelovimab	Tixagevimab/ cilgavimab
Alpha B.1.1.7	likely effective	likely effective	likely effective	likely effective	likely effective
Beta/ Gamma BA1.351/ P.1	likely ineffective	likely effective	likely effective	likely effective	likely effective
Delta B.1.617.2	likely effective	likely effective	likely effective	likely effective	likely effective
Omicron BA.1/ BA.1.1	likely ineffective	likely ineffective	likely effective	likely effective	unknown
Omicron BA.2	likely ineffective	likely ineffective	likely ineffective	likely effective	likely effective
Omicron BA.5	likely ineffective	likely ineffective	likely ineffective	likely effective	likely effective
Omicron BA.4.6	likely ineffective	likely ineffective	likely ineffective	likely effective	likely ineffective
Omicron BQ.1.1	likely ineffective	likely ineffective	likely ineffective	likely ineffective	likely ineffective

**Table 1.** Predicted efficacy by variant from *Davis et al.* (not updated for more recent variants). ■: likely effective ■: likely ineffective □: unknown. Submit updates.

viral entry into human cells and neutralizing the virus. These antibodies are derived from the B cells of recovered patients or immunized animals and are produced in large quantities using recombinant DNA technology and cell culture methods.

### Analysis

We analyze all significant controlled studies of amubarvimab for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random-effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, Randomized Controlled Trials (RCTs), and higher quality studies.

### Treatment timing

Fig. 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early treatment refers to treatment immediately or soon after symptoms ap-

pear, while late treatment refers to more delayed treatment.


## Variant Dependence

Extensive mutations in SARS-CoV-2 have resulted in variants that evade neutralizing antibodies from monoclonal antibody treatments<sup>49,50</sup>, resulting in efficacy that is highly variant dependent. Table 1 shows efficacy by variant for several monoclonal antibodies. This table covers earlier SARS-CoV-2 variants and has not been updated for more recent variants and more recent monoclonal antibodies.

## Results

Table 2 summarizes the results for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Table 3 shows results by treatment stage. Fig. 3 shows a timeline of the results in amubarvimab studies. Fig. 4 plots individual results by treatment stage. Fig. 5, 6, 7, 8, 9, 10, and 11 show forest plots for random-ef-

fects meta-analysis of all studies with pooled effects, mortality results, ICU admission, hospitalization, recovery, viral clearance, and long COVID.




**Fig. 2.** Treatment stages.

	Relative Risk	Studies	Patients	Early treatment	Late treatment
All studies	0.75 [0.34-1.70]	4	1,568	0.09 [0.01-0.70] *	0.97 [0.50-1.89]
After exclusions	0.56 [0.21-1.45]	3	1,228	0.09 [0.01-0.70] *	0.77 [0.37-1.62]
RCTs	0.39 [0.03-4.56]	2	1,134	0.09 [0.01-0.70] *	1.15 [0.54-2.41]
Mortality	0.75 [0.34-1.70]	4	1,568	0.09 [0.01-0.70] *	0.97 [0.50-1.89]
Hospitalization	0.63 [0.27-1.46]	2	1,120	0.39 [0.22-0.68] **	0.92 [0.87-0.97] **
Viral	0.93 [0.89-0.98] **	2	434		0.93 [0.89-0.98] **
RCT mortality	0.39 [0.03-4.56]	2	1,134	0.09 [0.01-0.70] *	1.15 [0.54-2.41]

**Table 2.** Random-effects meta-analysis for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Results show the relative risk with treatment and the 95% confidence interval. \* p<0.05 \*\* p<0.01.


**Table 3.** Random-effects meta-analysis results by treatment stage. Results show the relative risk with treatment and the 95% confidence interval. \* p<0.05 \*\* p<0.01.

### Timeline of COVID-19 amubarvimab studies (pooled effects)




**Fig. 3.** Timeline of results in amubarvimab studies.

### Efficacy in COVID-19 amubarvimab studies (pooled effects)




**Fig. 4.** Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random-effects meta-analysis.

## 4 amubarvimab COVID-19 studies




**Fig. 5. Random-effects meta-analysis for all studies.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

## 4 amubarvimab COVID-19 mortality results



**Fig. 6. Random-effects meta-analysis for mortality results.**


## 1 amubarvimab COVID-19 ICU result



**Fig. 7. Random-effects meta-analysis for ICU admission.**

## 2 amubarvimab COVID-19 hospitalization results


c19early.org  
June 2026



**Fig. 8.** Random-effects meta-analysis for hospitalization.

## 1 amubarvimab COVID-19 recovery result


c19early.org  
June 2026



**Fig. 9.** Random-effects meta-analysis for recovery.


## 2 amubarvimab COVID-19 viral clearance results

c19early.org  
June 2026



**Fig. 10.** Random-effects meta-analysis for viral clearance.


# 1 amubarvimab COVID-19 long COVID result



**Fig. 11. Random-effects meta-analysis for long COVID.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

## Randomized Controlled Trials (RCTs)

Fig. 12 shows a comparison of results for RCTs and observational studies. Fig. 13 shows a forest plot for random-effects meta-analysis of all Randomized Controlled Trials. RCT results are included in Table 2 and Table 3.



**Fig. 12. Results for RCTs and observational studies.**

### RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases<sup>52</sup>, and analysis of double-blind RCTs has identified extreme levels of bias<sup>53</sup>. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

### Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or other organizations with conflicts of interest, for example governments that previously denied treatment with the study drug. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. *Bekelman et al.* and *Lundh et al.* show that industry-sponsored studies are more likely to be favorable. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.


### RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 223 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

### Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates.

We performed a similar analysis across the 223 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03]<sup>60</sup>. Similar results are found for all low-cost treatments, RR 0.98 [0.90-1.07]. High-cost treatments show a non-significant trend towards



**Fig. 14. For COVID-19, observational study results do not systematically differ from RCTs, RR 0.97 [0.91-1.03] across 223 treatments<sup>57</sup>.**

RCTs showing greater efficacy, RR 0.93 [0.84-1.02]. Details can be found in the supplementary data.

Lee *et al.* showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see<sup>62,63</sup>.

### RCTs may be less reliable

Concato *et al.* report a paradoxical finding—RCT results had higher variability, and only RCTs were found to sometimes report significant results the opposite of the overall result. The same trend is seen for the most popular (most politicized) COVID-19 treatments—considering all statistically significant results reported in studies, RCTs are slightly more likely to report a result in the opposite direction. In other words, for these COVID-19 treatments and for the topics covered by Concato *et al.*, assuming causality from a single study is more likely to result in an incorrect conclusion for RCTs.

Increased risk of inconsistent results for RCTs suggests higher prevalence of bias, which may arise due to many issues including design bias, conflicts of in-

terest, treatment differences by physicians aware of allocation, attrition bias, ascertainment bias, randomization failures, errors, or fraud.

### Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)


Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $>0\%$  increased risk from  $\geq 3$  studies. Of these, 56% have been confirmed in RCTs, with a mean delay of 7.6 months (62% with 8.7 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

### All studies must be carefully analyzed

Neither observational studies nor RCTs prove causation—any study can be flawed or fraudulent. We need much more, for example a combination of results from many independent teams, detailed understanding of each study, knowledge of conflicts/team reliability, dose-response relationships, delay-response relationships, logical results across outcomes, or details consistent with pre-clinical expectations.

All studies must be evaluated individually. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta-analyses.

## 2 amubarvimab COVID-19 Randomized Controlled Trials



**Fig. 13. Random-effects meta-analysis for all Randomized Controlled Trials.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.


## Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which can be easily influenced by potential bias, may ignore or underemphasize serious issues not captured in the checklists, and may overemphasize issues unlikely to alter outcomes in specific cases (for example certain specifics of randomization with a very large effect size and well-matched baseline characteristics).

The studies excluded are as below. Fig. 15 shows a forest plot for random-effects meta-analysis of all studies after exclusions.

Yalan, unadjusted differences between groups.

### 3 amubarvimab COVID-19 studies after exclusions



**Fig. 15. Random-effects meta-analysis for all studies after exclusions.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.


## Media Bias

Low-cost treatments were subject to bias and censorship during the pandemic. Scientific bias is seen in the design, analysis, presentation, and selective reporting of studies, which favored negative results. A similar bias is seen in the media coverage for low-cost treatments. However, the opposite is seen for high-profit treatments.

We analyze media coverage for the 223 treatments we cover using Altmetric<sup>65</sup>, which reports the number of ~12,000 tracked news outlets that covered each study<sup>66</sup>. Studies are considered to have received significant media coverage if they were covered by at least 0.5% of the tracked news outlets. Fig. 16 and 17 show the bias toward positive results for high-profit treatments, in contrast to the opposite bias for low-cost treatments. This may result in widespread incorrect perceptions on the relative efficacy of high-profit and low-cost treatments. The impact is significant—increased cost limits the use of high-profit treatments and treatment equity, and high-profit treatments were also more difficult to access, especially for earlier treatment which improves efficacy and minimizes community transmission.

### Media coverage for COVID-19 high-profit treatments

Media selectively covered positive studies for high-profit treatments




**Fig. 16. Mainstream media was biased towards positive results for high-profit treatments.**

### Media censorship for COVID-19 low-cost treatments

Media selectively covered negative studies for low-cost treatments


Only 18 positive studies were covered:

fluvoxamine (3), HCQ (2), antiandrogens (2), budesonide (2), vitamin D, melatonin, probiotics, ivermectin, cannabidiol, famotidine, curcumin, resveratrol, UDCA



53 negative studies were covered:

HCQ (15), ivermectin (7), lopinavir/r. (5), vitamin D (5), azithromycin (4), zinc (2), vitamin C (2), metformin (2), fluvoxamine (2), indomethacin, colchicine, selenium, probiotics, vitamin A, ibuprofen, antiandrogens, vitamin B9, cannabidiol



**Fig. 17. In contrast to the results for high-profit treatments, mainstream media was biased against positive results for low-cost treatments.**

A combination of factors may have led to the media's suppression of low-cost treatments:

- Politicization led to a media environment where coverage was often framed to support a political narrative rather than to provide objective scientific information. As Scott Alexander said: "if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele." There was strong social pressure to discredit low-cost treatments.
- Censorship of information conflicting with selected authorities. For example, individuals and organizations presenting conflicting science were often banned on Twitter and YouTube.
- FDA requires "no adequate, approved, and available alternatives" in order to grant an EUA for novel high-profit interventions, creating a strong incentive for authorities to ignore or downplay existing low-cost treatments.
- Regulatory capture biases authorities towards high-profit interventions.
- Authorities ignored most evidence for low-cost treatments, for example the NIH references only 2% of studies in delayed, rarely-updated, biased commentaries with no quantitative analysis.
- Media coverage of science is often not very accurate, e.g., misunderstanding confounding issues. For example the media widely considered the RECOVERY HCQ RCT to be conclusive on efficacy, but very late treatment of late stage patients (mostly on oxygen already) with an excessive toxic dose (shown dangerous in a dose comparison RCT) provides no information on the recommended early/prophylactic treatment. With difficulting in understanding basic confounders like treatment delay and dose, the media may favor deferring to authorities. Many studies for low-cost treatments require greater expertise to analyze. Relatively few journalists have a strong ability to analyze clinical trials and are outnumbered by the rest.
- Substantial funding from pharmaceutical advertising biases editorial decisions towards high-profit interventions.
- PR power - companies/teams with strong PR presence are favored in the media, which correlates with high-profit and high conflict of interest studies.
- The media was very negative in general, inflating risk, fear, and anxieties. A negative bias may improve ratings and revenue, increasing motivation to continue watching coverage. A combination of low-cost treatments greatly reducing risk conflicts with the negative narrative.

## Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:


### Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours<sup>67,68</sup>. Baloxavir marboxil studies for influenza also show that treatment delay is critical — Ikematsu *et al.* report an 86% reduction in cases for post-exposure prophylaxis, Hayden *et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and Kumar *et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases <sup>69</sup>
<24 hours	-33 hours symptoms <sup>70</sup>
24-48 hours	-13 hours symptoms <sup>70</sup>
Inpatients	-2.5 hours to improvement <sup>71</sup>

**Table 4.** Studies of baloxavir marboxil for influenza show that early treatment is more effective.

Fig. 18 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 223 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.



**Fig. 18.** Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 223 treatments.

### Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in López-Medina *et al.*

### SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants<sup>73</sup>, for example the Gamma variant shows significantly different characteristics<sup>74-77</sup>. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants<sup>78,79</sup>.

### Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

### Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. Williams *et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. Xu *et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

### Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic<sup>82-102</sup>, therefore efficacy may depend strongly on combined treatments.

### Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

### Meta-analysis

The distribution of studies will alter the outcome of a meta-analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta-analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta-analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

## Pooled Effects

### Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. "The studies reported different outcomes" is not a good reason for disregarding

results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

### Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.


### Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.


### Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.


Analysis of the the association between different outcomes across studies from all 223 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Fig. 19 shows that lower hospitalization is very strongly associated with lower mortality ( $p < 0.000000000001$ ). Similarly, Fig. 20 shows that improved recovery is very strongly associated with lower mortality ( $p < 0.000000000001$ ). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with  $p = 0.003$  after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Fig. 21 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from  $p = 0.000000011$  to  $p = 0.0000000032$ .



**Fig. 19.** Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.



**Fig. 20.** Improved recovery is associated with lower mortality, supporting pooled outcome analysis.




**Fig. 19.** Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

### Pooled outcomes identify efficacy 5 months faster (8 months for RCTs)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $>0\%$  increased risk from  $\geq 3$  studies. 85% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.6 months. When restricting to RCTs only, 54% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 8.1 months. Fig. 22 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.

## Time when COVID-19 studies showed efficacy



**Fig. 22.** The time when studies showed that treatments were effective, defined as statistically significant improvement of  $\geq 10\%$  from  $\geq 3$  studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

## Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as differences in treatment delay are more likely to hide efficacy.

## Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta-analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

## Discussion


## Publication bias

Publishing is often biased towards positive results. Trials with patented drugs may have a financial conflict of interest that results in positive studies being more likely to be published, or bias towards more positive results. For example with molnupiravir, trials with negative results remain unpublished to date (CTRI/2021/05/033864 and CTRI/2021/08/0354242). For amubarvimab, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide

more opportunities for the specifics of data extraction and adjustments to influence results.

Fig. 23 shows a scatter plot of results for prospective and retrospective studies.



**Fig. 23.** Prospective vs. retrospective studies. The diamonds show the results of random-effects meta-analysis.

## Limitations

Summary statistics from meta-analysis necessarily lose information. As with all meta-analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone<sup>82-102</sup>. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Reviews

Focosi (C) et al. present a review covering amubarvimab for COVID-19.

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 500+ host and viral proteins and other factors<sup>40-47</sup>, providing many therapeutic targets. Over 11,000 compounds have been predicted to reduce COVID-19 risk<sup>48</sup>, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Fig. 24 shows an overview of the results for amubarvimab in the context of multiple COVID-19 treatments, and Fig. 25 shows a plot of efficacy vs. cost for COVID-19 treatments.




Fig. 24. Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random-effects meta-analysis. 0.5% of 11,000+ proposed treatments show efficacy<sup>104</sup>.




Fig. 25. Efficacy vs. cost for COVID-19 treatments.

Conclusion

Significantly lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit. Meta-analysis using the most serious outcome reported shows 25% [-70-66%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials and higher quality studies. Early treatment shows efficacy while late treatment does not, consistent with expectations for an antiviral treatment.

Currently there is limited data, with only 31 control events for the most serious outcome in trials to date.

Efficacy is variant dependent. mAb use may create new variants that spread globally<sup>1-3</sup>, and may be associated with increased risk of autoimmune disease<sup>4</sup>, prolonged viral loads, clinical deterioration, and immune escape<sup>2,5-9</sup>.

Contact. Contact us on X at @CovidAnalysis.

Funding. We have received no funding or compensation in any form, and do not accept donations. This is entirely volunteer work.

Conflicts of interest. We have no conflicts of interest. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

Disclaimer. We do not provide medical advice. No treatment is 100% effective, and all may have side effects. Protocols combine multiple treatments. Consult a qualified physician for personalized risk/benefit analysis.

AI. We use AI models (Gemini, Grok, Claude, and ChatGPT) tasked with functioning as additional peer-reviewers to check for errors, suggest improvements, and review spelling and grammar. Any corrections are verified and applied manually. Our preference for em dashes is independent of AI.


Dedication. This work is dedicated to those who risked their career to save lives under extreme censorship and persecution from authorities and media that have not even reviewed most of the science. In alphabetical order, those that paid the ultimate price: Dr. Thomas J. Borody, Dr. Jackie Stone, Dr. Vladimir (Zev) Zelenko; and those that continue to risk their careers to save lives: Dr. Mary Talley Bowden, Dr. Flavio Cadegiani, Dr. Shankara Chetty, Dr. Ryan Cole, Dr. George Fareed, Dr. Sabine Hazan, Dr. Pierre Kory, Dr. Tess Lawrie, Dr. Robert Malone, Dr. Paul Marik, Dr. Peter McCullough, Dr. Didier Raoult, Dr. Harvey Risch, Dr. Brian Tyson, Dr. Joseph Varon, and the estimated over one million physicians worldwide that prescribed one or more low-cost COVID-19 treatments known to reduce risk, contrary to authority beliefs.

Public domain. This is a public domain work distributed in accordance with the Creative Commons CC0 1.0 Universal license, which dedicates the work to the public domain by waiving all rights worldwide under copyright law. You can distribute, remix, adapt, and build upon this work in any medium or format, including for commercial purposes, without asking permission. Referenced material and third-party images retain any original copyrights or restrictions. See: <https://creativecommons.org/publicdomain/zero/1.0/>.

## Study Notes

### Evering

#### Amubarvimab/r.. ACTIV-2/A5401 EARLY TREATMENT RCT



Is early treatment with amubarvimab beneficial for COVID-19?  
Double-blind RCT 780 patients in multiple countries (Jan - Jul 2021)

**Lower mortality (p=0.006) and hospitalization (p=0.00082)**


Evering et al., eClinicalMedicine, Aug 2024

c19early.org

RCT 780 high-risk non-hospitalized COVID-19 patients showing significantly lower risk of hospitalization or death through 36 weeks, but no significant difference in long COVID with amubarvimab/romlusevimab treatment compared to placebo.

### Qu

#### Amubarvimab/r.. Qu et al. ICU PATIENTS



Is **very late** treatment with amubarvimab beneficial?  
PSM retrospective 121 patients in China (December 2022 - March 2023)

**Lower mortality with amubarvimab (not stat. sig., p=0.058)**


Qu et al., Heliyon, September 2024

c19early.org

Retrospective 121 severe ICU COVID-19 patients in China showing lower 28-day mortality and ICU mortality with amubarvimab-romlusevimab treatment compared to no antiviral treatment. No significant differences were found in viral conversion rate or thromboembolic events. After propensity score matching to balance baseline characteristics, the mortality differences were no longer statistically significant.

### Self

#### Amubarvimab/r.. ACTIV-3/TICO LATE TREATMENT RCT



Is **late** treatment with amubarvimab beneficial for COVID-19?

Double-blind RCT 354 patients in multiple countries (Dec 2020 - Mar 2021)  
Trial underpowered for serious outcomes


Self et al., The Lancet Infectious Dis., Dec 2021

c19early.org

RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to fertility. Long-term results are reported in Mourad et al.

### Yalan

#### Amubarvimab/r.. Yalan et al. LATE TREATMENT



Is **late** treatment with amubarvimab beneficial for COVID-19?

Retrospective 340 patients in China (October - November 2022)

**Shorter hospitalization (p=0.004) and faster viral clearance (p=0.004)**

Yalan et al., BMC Pharmacology and Tox., Apr 2024

c19early.org

Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy for improving clinical outcomes among severe or critical cases.

## Appendix 1. Methods and Data

### Search methods

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org, which regularly receives notification of studies upon publication. Search terms are amubarvimab and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of amubarvimab for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded.


## Effect extraction

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome-specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with hospitalization/death than later viral load reduction<sup>106</sup>. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO<sub>2</sub> is more important than cough.

## Statistical methods

Forest plots are computed using PythonMeta<sup>107</sup> with the DerSimonian and Laird random-effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the  $I^2$  statistic. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to Zhang *et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed Altman, Altman (B), and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1<sup>111</sup>. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.14.5) with scipy (1.17.1), pythonmeta (1.26), numpy (2.4.6), statsmodels (0.14.6), and plotly (6.7.0). Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

When evaluating potential effect modification across groups, we use an interaction test as described by Altman (C) *et al.* We compared the log-transformed relative risks using a *z*-test, deriving the standard error of the difference from



**Fig. 26.** Mid-recovery results can more accurately reflect efficacy when almost all patients recover. Mateja *et al.* confirm that intermediate viral load results more accurately reflect hospitalization/death.

the 95% confidence intervals. A two-sided interaction *p*-value of < 0.05 was considered a statistically significant difference in treatment effect between the groups.

## Quality evaluation

Cochrane RoB 2/ROBINS-I are often used to evaluate studies, and have the advantage of providing standardized rules that can be applied with minimal understanding of the domain and study. However, the rules do not account for many real-world issues, often overemphasize or underemphasize others, and studies show low inter-rater reliability<sup>119</sup>. Certain domains are more applicable for these tools, however the time-sensitive nature of a pandemic, with significant mortality for every day of delay in evidence assessment, and the characteristics of COVID-19 make them inappropriate for this domain. This can be demonstrated with examples where expert RoB 2/ROBINS-I ratings do not match reality for COVID-19. Popp *et al.* use RoB 2 to classify Reis *et al.* as low risk of bias, however this is the opposite of reality—the trial not only has very high risk of bias, but has very high actual known bias, refusing to release data despite pledging to, reporting multiple impossible numbers, having blinding and randomization failure, and many other issues<sup>121</sup>. Axfors *et al.* use RoB 2 to classify Horby *et al.* as low risk of bias, however this is the opposite of reality—the very late treatment and excessive dosage used produces results with no relevance to recommended usage. HCQ shows poor results with late treatment and excessive dosage, and the combination shows harm<sup>B</sup>. Hempenius *et al.* use ROBINS-I to classify 33 studies for HCQ. The two rated as having the lowest risk of bias<sup>117,118</sup> are far from the most informative. Both involve very late treatment, providing no information on recommended usage, and ROBINS-I does a very poor job of accounting for the impact of confounding factors<sup>C</sup>.

Our quality evaluation focuses on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias. The estimated potential impact of each confounding factor, and the direction of the impact is considered. For example, consider a study that shows significantly lower risk, the value of the study varies significantly if confounding points to an underestimate or an overestimate of efficacy. In one case, the real effect may be null, while the other case provides stronger evidence of efficacy (which may be greater than the study shows). Analysis focusing on the risk of bias, while simpler, may penalize studies for theoretical or technical issues that have no or minimal impact on outcomes. Analysis also depends on the outcome, for example certain issues are less relevant for objective outcomes such as mortality. Inaccurate penalization, and inaccurate high-quality evaluation in the face of known major issues affecting outcomes, increases in significance during a pandemic when immediate recognition of new evidence is critical, and when considering all global studies, as required during a pandemic. Investigators in other countries may have different customs for design, analysis, and reporting, and different English language skills, however they may not be less diligent or have greater bias. Investigators in lower-pharmaceutical-profit countries may have lower bias towards profitable interventions.

## Treatment time

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective<sup>67,68</sup>.

## Living analysis

This is a living analysis and is updated regularly. We received no funding, this research is done in our spare time. We have no affiliation with any pharmaceu-

tical companies, supplement companies, governments, political parties, or advocacy organizations.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/ammeta.html>.

## Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Evering, 8/16/2024, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, median age 49.0, 14 authors, study period January 2021 - July 2021, trial NCT04518410 (history) (ACTIV-2/A5401).	risk of death, 90.9% lower, RR 0.09, $p = 0.006$ , treatment 1 of 390 (0.3%), control 11 of 390 (2.8%), NNT 39, day 252.
	risk of long COVID, 20.5% higher, RR 1.20, $p = 0.39$ , treatment 53 of 390 (13.6%), control 44 of 390 (11.3%), day 252.
	risk of hospitalization, 61.0% lower, RR 0.39, $p < 0.001$ , treatment 16 of 390 (4.1%), control 41 of 390 (10.5%), NNT 16, day 252.
	risk of death/hospitalization, 67.3% lower, RR 0.33, $p < 0.001$ , treatment 17 of 390 (4.4%), control 52 of 390 (13.3%), NNT 11, day 252.

## Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Qu, 9/30/2024, retrospective, China, peer-reviewed, 12 authors, study period December 2022 - March 2023.	risk of death, 46.0% lower, HR 0.54, $p = 0.06$ , treatment 47, control 47, propensity score matching, Kaplan-Meier, day 40.
	risk of no viral clearance, 3.8% lower, HR 0.96, $p = 0.89$ , treatment 47, control 47, inverted to make HR<1 favor treatment, propensity score matching, Kaplan-Meier, day 40.
Self, 12/23/2021, Double Blind Randomized Controlled Trial, multiple countries, peer-reviewed, 67 authors, study period 16 December, 2020 - 1 March, 2021, average treatment delay 8.0 days, trial NCT04501978 (history) (ACTIV-3/TICO).	risk of death, 15.0% higher, RR 1.15, $p = 0.72$ , treatment 15 of 176 (8.5%), control 13 of 178 (7.3%), adjusted per study, day 90.
	risk of no recovery, 7.4% lower, RR 0.93, $p = 0.48$ , treatment 21 of 176 (11.9%), control 27 of 178 (15.2%), adjusted per study, inverted to make RR<1 favor treatment, day 90, primary outcome.
	risk of no recovery, no change, RR 1.00, $p = 0.99$ , treatment 173, control 178, adjusted per study, inverted to make RR<1 favor treatment, pulmonary-plus ordinal outcome @day 5, day 5.
Yalan, 4/19/2024, retrospective, China, peer-reviewed, median age 72.0, 6 authors, study period October 2022 - November 2022, excluded in	risk of death, 71.4% higher, RR 1.71, $p = 0.35$ , treatment 12 of 170 (7.1%), control 7 of 170 (4.1%).

exclusion analyses: unadjusted differences between groups.	risk of ICU admission, 7.7% higher, RR 1.08, $p = 0.80$ , treatment 42 of 170 (24.7%), control 39 of 170 (22.9%).
	hospitalization time, 7.7% lower, relative time 0.92, $p = 0.004$ , treatment 170, control 170.
	time to viral-, 6.7% lower, relative time 0.93, $p = 0.004$ , treatment 170, control 170.

## Supplementary Data

Supplementary Data

## Footnotes

- Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.
- When administered late in infection, HCQ may enhance viral egress by further increasing lysosomal pH beyond the effect of ORF3a's water channel activity, thereby promoting lysosomal exocytosis, inactivating degradative enzymes, and facilitating the release of SARS-CoV-2 particles into the extracellular environment<sup>113,114</sup>. Research also suggests potential cardioprotective effects at lower doses, but cardiotoxicity with excessive dosage<sup>115</sup>. *Bobrowski et al.* also indicate negative effects if HCQ and remdesivir are combined.
- Peters et al.* is subject to confounding by calendar-time (SOC evolved rapidly early in the pandemic, the linear covariate does not reflect non-linear SOC changes and hospital specific effects), hospital type (non-treatment hospitals were tertiary university centers), confounding by indication (4/7 hospitals initiated treatment on deterioration), immortal-time bias for as-treated (exposure assigned after baseline), significant differences for other experimental treatments, potential overadjustment from collider bias (steroid use and indication bias), limited baseline severity information, differences in hospice referral propensity across hospitals, unadjusted difference in time from onset to admission, difference in PCR positivity, and other factors. *Mahévas et al.* is subject to confounding by hospital (treatment highly dependent on the hospital, different SOC/ICU transfer practices, not included in PS), immortal time (only partly addressed in sensitivity analysis), co-treatment differences, calendar-time (SOC evolved rapidly early in the pandemic), binary coding for age (age  $\geq 65$  despite steep age-risk gradient), residual imbalance (variables dropped from PS), a composite outcome dependent on hospital triage/capacity, and other factors.

## References

- Focosi et al.*, Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment, Drug Resistance Updates, doi:10.1016/j.drug.2023.100991.
- Leducq et al.*, Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies, The Journal of Infectious Diseases, doi:10.1093/infdis/jiad523.
- Bruhn et al.*, Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies, eBioMedicine, doi:10.1016/j.ebiom.2025.105770.
- Ngiam et al.*, Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2026.108435.
- Choudhary et al.*, Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy, medRxiv, doi:10.1101/2021.09.03.21263105.

6. **Günther** et al., Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection, medRxiv, doi:10.1101/2024.01.06.24300890.
7. **Casadevall** et al., Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship, *Clinical Infectious Diseases*, doi:10.1093/cid/ciae408.
8. **Focosi (B)** et al., The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?, *Infection and Drug Resistance*, doi:10.2147/IDR.S540928.
9. **Martin-Blondel** et al., Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study, *iScience*, doi:10.1016/j.isci.2025.114226.
10. **Ryu** et al., Fibrin drives thromboinflammation and neuropathology in COVID-19, *Nature*, doi:10.1038/s41586-024-07873-4.
11. **Rong** et al., Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19, *Cell Host & Microbe*, doi:10.1016/j.chom.2024.11.007.
12. **Yang** et al., SARS-CoV-2 infection causes dopaminergic neuron senescence, *Cell Stem Cell*, doi:10.1016/j.stem.2023.12.012.
13. **Scardua-Silva** et al., Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
14. **Hampshire** et al., Cognition and Memory after Covid-19 in a Large Community Sample, *New England Journal of Medicine*, doi:10.1056/NEJMoa2311330.
15. **Duloquin** et al., Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2, *Journal of Clinical Medicine*, doi:10.3390/jcm13051397.
16. **Sodagar** et al., Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches, *Biomolecules*, doi:10.3390/biom12070971.
17. **Sagar** et al., COVID-19-associated cerebral microbleeds in the general population, *Brain Communications*, doi:10.1093/braincomms/fcae127.
18. **Verma** et al., Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations, *bioRxiv*, doi:10.1101/2024.06.02.596989.
19. **Panagea** et al., Neurocognitive Impairment in Long COVID: A Systematic Review, *Archives of Clinical Neuropsychology*, doi:10.1093/arclin/aca042.
20. **Ariza** et al., COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations, *Biomedicines*, doi:10.3390/biomedicines12061147.
21. **Vashisht** et al., Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications, *Viruses*, doi:10.3390/v16081183.
22. **Ahmad** et al., Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium, *The Neurohospitalist*, doi:10.1177/19418744241292487.
23. **Wang** et al., SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction, *Translational Neurodegeneration*, doi:10.1186/s40035-024-00458-1.
24. **Freitas** et al., Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19, *Scientific Reports*, doi:10.1038/s41598-025-08632-9.
25. **Lu** et al., Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis, *Nature Communications*, doi:10.1038/s41467-025-61961-1.
26. **Jachman-Kapufka** et al., Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study, *Brain Sciences*, doi:10.3390/brainsci14111161.
27. **Beckman** et al., SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19, *Cell Reports*, doi:10.1016/j.celrep.2022.111573.
28. **Eberhardt** et al., SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, *Nature Cardiovascular Research*, doi:10.1038/s44161-023-00336-5.
29. **Van Tin** et al., Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF- $\kappa$ B Signaling, *Cells*, doi:10.3390/cells13161331.
30. **Borka Balas** et al., COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice, *Reviews in Cardiovascular Medicine*, doi:10.31083/j.rcm2405125.
31. **Altaweel** et al., An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID-19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies, *Archives of Microbiology & Immunology*, doi:10.26502/ami.936500177.
32. **Saha** et al., COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications, *Science Progress*, doi:10.1177/00368504251322069.
33. **Yin** et al., COVID-19: a vascular nightmare unfolding, *Frontiers in Immunology*, doi:10.3389/fimmu.2025.1593885.
34. **Bruno** et al., Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study, *European Heart Journal*, doi:10.1093/eurheartj/ehaf430.
35. **Abiri** et al., The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors, *BMC Infectious Diseases*, doi:10.1186/s12879-025-11419-y.
36. **Gioia** et al., SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence, *Nature Cell Biology*, doi:10.1038/s41556-023-01096-x.
37. **Doğan** et al., Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients, *Current Issues in Molecular Biology*, doi:10.3390/cimb45020062.
38. **Rueda-Torres** et al., Longitudinal Assessment of DNA Damage in PBMCs From Hospitalized COVID-19 Patients via Alkaline Comet Assay, *Environmental and Molecular Mutagenesis*, doi:10.1002/em.70055.
39. **Trender** et al., Changes in memory and cognition during the SARS-CoV-2 human challenge study, *eClinicalMedicine*, doi:10.1016/j.eclinm.2024.102842.
40. **Dugied** et al., Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization, *Communications Biology*, doi:10.1038/s42003-025-07933-z.
41. **Malone** et al., Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design, *Nature Reviews Molecular Cell Biology*, doi:10.1038/s41580-021-00432-z.
42. **Murigneux** et al., Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly, *Nature Communications*, doi:10.1038/s41467-024-44958-0.
43. **Lv** et al., Host proviral and antiviral factors for SARS-CoV-2, *Virus Genes*, doi:10.1007/s11262-021-01869-2.
44. **Lui** et al., Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling, *Virology*, doi:10.1128/mbio.00392-24.
45. **Niarakis** et al., Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, *Frontiers in Immunology*, doi:10.3389/fimmu.2023.1282859.
46. **Katiyar** et al., SARS-CoV-2 Assembly: Gaining Infectivity and Beyond, *Viruses*, doi:10.3390/v16111648.
47. **Wu** et al., Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition, *RNA Biology*, doi:10.1080/15476286.2024.2433830.
48. **c19early.org**, [c19early.org/treatments.html](https://c19early.org/treatments.html).
49. **Hattab** et al., SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants, *Infection*, doi:10.1007/s15010-024-02223-y.

50. **Focosi (C)**, D., *Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities*, Current Topics in Microbiology and Immunology, doi:10.1007/82\_2024\_268.
51. **Davis** et al., *The Promise and Peril of Anti-SARS-CoV-2 Monoclonal Antibodies*, Clinical Infectious Diseases, doi:10.1093/cid/ciac902.
52. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.
53. **Gøtzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.
54. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.
55. **Bekelman** et al., *Scope and Impact of Financial Conflicts of Interest in Biomedical Research*, JAMA, doi:10.1001/jama.289.4.454.
56. **Lundh** et al., *Industry sponsorship and research outcome*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000033.pub3.
57. **c19early.org (B)**, c19early.org/amsupp.html#fig\_rctobs.
58. **Concato** et al., *Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs*, New England Journal of Medicine, doi:10.1056/NEJM200006223422507.
59. **Anglemyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000034.pub2.
60. **c19early.org (C)**, c19early.org/rctobs.html.
61. **Lee** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.
62. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.
63. **Nichol** et al., *Challenging issues in randomised controlled trials*, Injury, 2010, doi:10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
64. **Yalan** et al., *Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7.
65. **altmetric.com**, www.altmetric.com/.
66. **help.altmetric.com**, help.altmetric.com/support/solutions/articles/6000235983-attention-sources-tracked-by-altmetric.
67. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
68. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
69. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.
70. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.
71. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.
72. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.
73. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.
74. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.
75. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.
76. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.
77. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, Research Square, doi:10.21203/rs.3.rs-910467/v1.
78. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, medRxiv, doi:10.1101/2022.01.03.21268111.
79. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, bioRxiv, doi:10.1101/2021.12.31.474653.
80. **Williams**, T., *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.
81. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.
82. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.
83. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
84. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.
85. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, Pathogens, doi:10.3390/pathogens10111514.
86. **Alsaidi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.
87. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
88. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.
89. **Wan** et al., *Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level*, Scientific Reports, doi:10.1038/s41598-024-54722-5.
90. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.
91. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.
92. **Xing** et al., *Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals*, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.
93. **Chen** et al., *Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Eb-selen and Remdesivir*, ACS Pharmacology & Translational Science, doi:10.1021/acspsci.1c00022.

94. **Hempel** et al., Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties, *Chemical Science*, doi:10.1039/D1SC01494C.
95. **Schultz** et al., Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2, *Nature*, doi:10.1038/s41586-022-04482-x.
96. **Ohashi** et al., Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment, *iScience*, doi:10.1016/j.isci.2021.102367.
97. **Al Krad** et al., The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication, *bioRxiv*, doi:10.1101/2025.03.09.642200.
98. **Abd Elsalam** et al., Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures, *AMB Express*, doi:10.1186/s13568-026-02030-8.
99. **Rana** et al., Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study, *In Silico Pharmacology*, doi:10.1007/s40203-026-00576-w.
100. **Setz** et al., Synergistic Virus Neutralizing Activities of European Black Elderberry Fruit Extract and Iota-Carrageenan Against SARS-CoV-2, Influenza A Virus and Respiratory Syncytial Virus, *Nutrients*, doi:10.3390/nu18081205.
101. **Ali** et al., Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection, *Journal of Medical Virology*, doi:10.1002/jmv.70713.
102. **Thairu** et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, *Journal of Pharmaceutical Research International*, doi:10.9734/jpri/2022/v34i44A36328.
103. **Singh** et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkac045.
104. **c19early.org (D)**, [c19early.org/timeline.html](https://c19early.org/timeline.html).
105. **Mourad** et al., Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial, *Clinical Microbiology and Infection*, doi:10.1016/j.cmi.2025.02.002.
106. **Mateja** et al., The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiaf282.
107. **Deng, H.**, PyMeta, Python module for meta-analysis, [www.pymeta.com/](http://www.pymeta.com/).
108. **Zhang** et al., What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, *JAMA*, 80:19, 1690, doi:10.1001/jama.280.19.1690.
109. **Altman, D.**, How to obtain the P value from a confidence interval, *BMJ*, doi:10.1136/bmj.d2304.
110. **Altman (B)** et al., How to obtain the confidence interval from a P value, *BMJ*, doi:10.1136/bmj.d2090.
111. **Sweeting** et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, *Statistics in Medicine*, doi:10.1002/sim.1761.
112. **Altman (C)** et al., Interaction revisited: the difference between two estimates, *BMJ*, doi:10.1136/bmj.326.7382.219.
113. **Michelucci** et al., SARS-CoV-2 ORF3a accessory protein is a water-permeable channel that induces lysosome swelling, *Communications Biology*, doi:10.1038/s42003-024-07442-5.
114. **Ghosh** et al.,  $\beta$ -Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway, *Cell*, doi:10.1016/j.cell.2020.10.039.
115. **Kamga Kapchoup** et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, *Frontiers in Pharmacology*, doi:10.3389/fphar.2023.1128382.
116. **Bobrowski** et al., Synergistic and Antagonistic Drug Combinations against SARS-CoV-2, *Molecular Therapy*, doi:10.1016/j.ymthe.2020.12.016.
117. **Peters** et al., Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine, *Clinical Microbiology and Infection*, doi:10.1016/j.cmi.2020.10.004.
118. **Mahévas** et al., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, *BMJ* 2020, doi:10.1136/bmj.m1844.
119. **Minozzi** et al., The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application, *Journal of Clinical Epidemiology*, doi:10.1016/j.jclinepi.2020.06.015.
120. **Popp** et al., Ivermectin for preventing and treating COVID-19, *Cochrane Database of Systematic Reviews*, doi:10.1002/14651858.CD015017.pub3.
121. **Reis** et al., Effect of Early Treatment with Ivermectin among Patients with Covid-19, *New England Journal of Medicine*, doi:10.1056/NEJMoa2115869.
122. **Axfors** et al., Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, *Nature*, doi:10.1038/s41467-021-22446-z.
123. **Horby** et al., Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial, *NEJM*, doi:10.1056/NEJMoa2022926.
124. **Hempenius** et al., Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19, *Pharmacoepidemiology and Drug Safety*, doi:10.1002/pds.5632.
125. **Evering** et al., Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial, *eClinicalMedicine*, doi:10.1016/j.eclinm.2024.102787.
126. **Qu** et al., Effect of amubarvimab-romlusevimab for treatment of severe COVID-19 in intensive care units: A retrospective cohort study, *Heliyon*, doi:10.1016/j.heliyon.2024.e37663.
127. **Self** et al., Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRIL-196 plus BRIL-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial, *The Lancet Infectious Diseases*, doi:10.1016/S1473-3099(21)00751-9.